Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in a deal valued at up to $5.8 ...
If you miss the days when you used Basic on your classic computer or wrote embedded software with a Basic Stamp, then maybe dust off your Arduino UNO or any similar AVR board and try nanoBASIC_UNO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results